CD46 Antibody Drug Conjugate Impedes Myeloma Engraftment in Patient-Derived Xenografts

Abstract

Multiple myeloma (MM) is incurable, implying that MM progenitor cells are inherently resistant to current agents and inevitably lead to relapse. We recently reported the potent anti-myeloma effect of an antibody-drug conjugate targeting CD46 conjugated to monomethyl auristatin F (MMAF) anti-tubulin payload (CD46-ADC). Interestingly, MM patients with high-risk gain of chromosome arm 1q (1q+), overexpress CD46 and primary cells with 1q+ are more sensitive to CD46-ADC. Thus, we hypothesized that CD46-ADC may have the unique potential to target 1q+ MM progenitors.